Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AHA rejects smokeless tobacco for smoking cessation

This article was originally published in The Tan Sheet

Executive Summary

Smokeless tobacco products are not appropriate alternatives to nicotine-replacement therapies, the American Heart Association says. A policy statement published online Sept. 13 in AHA's journal Circulation notes that, despite the push for smokeless tobacco as a risk-reduction strategy for smokers, the association "does not recommend the use of ST as an alternative to cigarette smoking or as a smoking-cessation product." Smokeless products, such as Phillip Morris' snus, produce plasma nicotine levels in users too low to make them as effective for cessation as NRTs, which "have an impressive safety record," according to the AHA team led by Mariann Piano of the University of Illinois at Chicago's Department of Biobehavioral Health Science. FDA is weighing Star Scientific's citizen petition for "modified-risk" claims for its smokeless tobacco products (1"The Tan Sheet" March 1, 2010)

You may also be interested in...

FDA's Tobacco Center To Mull First Modified-Risk Claim Application

FDA will have a complex public health impact equation to balance as its Center for Tobacco Products faces its first application for "modified-risk" tobacco product claims

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts